Clinical Trial Update: A Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based Treatment [Phase 3]

View source ↗

Summary

Phase III trial evaluating WX390 in combination with toripalimab versus investigator's choice in recurrent or metastatic cervical cancer after platinum-based th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• Toripalimab (Toripalimab)
• WX390

Snippet

Sponsor: Shanghai Jiatan Pharmatech Co., Ltd | Conditions: Cervical Cancer Metastatic | Phase 3 | Status: NOT_YET_RECRUITING